Featured

Status

All Statuses
  • Completed36

Health Topics

Any Category
Chemicals and Drugs
Amino Acids, Peptides, and Proteins
Clear Filters

Search Clinical Trials

36 Results
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role: Lead Sponsor
Completed
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
Before starting in the treatment part of this study, leukemia cells and skin fibroblasts will be collected from the patient - called "procurement" - to allow us to make the …
Baylor Role: Lead Sponsor
Completed
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer
The development of a clinical trial for gene therapy in prostate cancer will be coordinated with our collaborators at Baylor involved in similar studies in order to facilitate the approval …
Baylor Role: Lead Sponsor
Completed
Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
The investigators have grown neuroblastoma cells in the laboratory and put into them two specially produced mouse viruses (retroviruses) that carry the lymphotactin and the IL-2 gene. These lymphotactin and …
Baylor Role: Lead Sponsor
Completed
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered …
Baylor Role: Collaborator
Completed
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs. Patients and controls …
Baylor Role: Collaborator